Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05675449

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept.

There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optimal dose(s) of elranatamab plus maplirpacept.

All study medicines are given over 4-week cycles. Everyone taking part in this study will receive elranatamab as a shot under the skin. Participants in Part 1 will also receive weekly carfilzomib as an IV infusion (given directly into a vein) and dexamethasone either by mouth (as a pill) or by IV infusion. Participants in Part 2 will receive elranatamab in combination with maplirpacept as an IV infusion (given directly into a vein)

The investigators will examine the experiences of people receiving the study medicines. This will help determine if the study medicines are safe and can be used for multiple myeloma treatment. Participants will take part in this study for about 2 years after the first dose.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Multiple Myeloma Blood Protein Disorders Cardiovascular Diseases Disease Attributes Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Paraproteinemias Pathologic Processes Pathological Conditions, Signs and Symptoms Recurrence Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Rambam Health Care Campus, Haifa, Israel

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Prior diagnosis of multiple myeloma as defined by IMWG criteria.
  • Measurable disease based on IMWG criteria as defined by at least 1 of the following:
  • Serum M-protein ≥0.5 g/dL.
  • Urinary M-protein excretion ≥200 mg/24 hours.
  • Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65).
  • Part 1: Received at least 1 but not more than 3 prior lines of therapy for multiple myeloma (induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as 1 line of therapy).
  • Part 2: Received at least 3 prior lines of therapy for multiple myeloma who are refractory to at least one IMiD, one PI and one anti-CD38 antibody.
  • ECOG performance status 0-1.
  • Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1.
  • Not pregnant or breastfeeding and willing to use contraception.

Exclusion criteria

  • Plasma cell leukemia, Smouldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome, Primary refractory MM
  • Impaired cardiovascular function or clinically significant cardiovascular diseases.
  • Participants with any active, uncontrolled bacterial, fungal, or viral infection.
  • Stem cell transplant within 12 weeks prior to enrollment, or active graft versus host disease.
  • Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
  • Part 1: Previous treatment with a BCMA-directed therapy.
  • Part 2: Previous treatment with any anti-BCMA directed therapy, with the exception of CAR-T. Previous treatment with a CD47-SIRP alpha-directed therapy.
  • Part 1: Prior treatment with carfilzomib
  • Live attenuated vaccine within 4 weeks of the first dose of study intervention.
  • Administration with an investigational product (e.g. drug or vaccine) concurrent with study intervention or within 30 days preceding the first dose of study intervention used in this study.
  • Any of the following within 3 months of enrollment: erosive esophagitis, treatment resistant peptic ulcer, infectious or inflammatory bowel disease, pulmonary embolism or uncontrolled thromboembolic event.
  • Intolerance to or participants who have had a severe (Grade ≥3) allergic or anaphylactic reaction to antibodies or therapeutic proteins

Treatment and study plan

Elranatamab

Drug

BCMA-CD3 bispecific antibody

Other names: PF-06863135

Carfilzomib

Drug

proteasome inhibitor

Other names: Kyprolis

Maplirpacept

Drug

CD47-SIRP alpha-directed

Other names: PF-07901801, TTI-622

Primary outcomes

  1. Part 1 Number of participants with dose limiting toxicity (DLT)

    Time frame: From first dose of elranatamab through the end of the first cycle of combination treatment, about 42 days.

    Dose limiting toxicity rate based on dose limiting toxicity evaluable participants.

  2. Part 2A Number of participants with dose limiting toxicity

    Time frame: From the first dose of maplirpacept through the first cycle of combination treatment, about 64 days.

    Dose limiting toxicity based on dose limiting toxicity evaluable participants.

  3. Part 2B Number of participants with dose limiting Toxicity

    Time frame: From first dose of elranatamab through the first cycle of combination treatment, about 42 days.

    Dose limiting toxicity rate based on dose limiting toxicity evaluable participants.

Secondary outcomes

  1. Part 1: Number of Participants with Treatment Emergent Adverse Events (TEAE) by Seriousness and Relationship to Treatment

    Time frame: Assessed from baseline up to 90 days after last dose of study treatment.

    Counts of participants who had TEAEs, defined as newly occurring or worsening after first dose. Relatedness to study drug was assessed by the investigator. Participants with multiple occurrences of an AE within a category were counted once within the category.

  2. Part 1: Number of Participants with Adverse Events (AE) characterized by type, frequency, severity.

    Time frame: Assessed from baseline up to 90 days after last dose of study treatment.

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

  3. Part 1: Number of Participants with Clinically Significant Change From Baseline in Laboratory Abnormalities

    Time frame: Accessed from baseline up to 90 days after the last dose of study treatment.

    Laboratory abnormalities as characterized by type, frequency, severity.

  4. Part 1: Percent of participants with Best Overall Response (BOR)

    Time frame: Assessed for approximately 2 years

    BOR is defined as the best response recorded from treatment start until disease progression/recurrence based on International Myeloma Working Group (IMWG) response criteria.

  5. Part 1: Percentage of Participants with an Objective Response Rate (ORR)

    Time frame: Assessed from enrollment for approximately 2 years.

    ORR rate is defined as the percent of participants having a Best Overall Response (BOR) of confirmed Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), or Partial Response (PR) according to IMWG.

  6. Part 1: Percentage of participants with a complete response rate (CRR)

    Time frame: Assessed for approximately 2 years

    Complete Response/ stringent Complete Response (CR+sCR) rate per IMWG response criteria as determined by investigator.

  7. Part 1: Time to Response (TTR)

    Time frame: Assessed for approximately 2 years.

    TTR is defined, for participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that is subsequently confirmed.

  8. Part 1: Duration of Response (DOR)

    Time frame: Assessed for approximately 2 years.

    DOR is defined, for participants with an objective response per IMWG criteria, as the time from the first documentation of objective response that is subsequently confirmed, until the first documentation of confirmed progressive disease (PD) per IMWG criteria.

  9. Part 1: Duration of Complete Response (DOCR)

    Time frame: Assessed for approximately 2 years.

    DOCR is defined, for participants with a Complete Response/stringent Complete Response (CR+sCR) per IMWG criteria, as the time from the first documentation of CR/sCR that is subsequently confirmed, until the first documentation of confirmed progressive disease (PD) per IMWG criteria.

  10. Part 1: Time of Progression Free Survival (PFS)

    Time frame: Assessed from enrollment until Progressive Disease or death for approximately 2 years.

    Progression free survival (IMWG response criteria)

  11. Part 1: Time of Overall Survival (OS)

    Time frame: Assessed for approximately 2 years

    OS is the duration of time from first dose of study treatment to death.

  12. Part 1: Minimal Residual Disease (MRD) Negativity Rate

    Time frame: Assessed for approximately 2 years

    MRD negativity rate is the proportion of participants acheiving CR+sCR with negative MRD, per IMWG sequencing criteria, from the date of first dose until the first documentation of confirmed progressive disease (PD), death or start of new anticancer therapy.

  13. Part 1: Concentrations of carfilzomib

    Time frame: Once approximately 7 weeks from enrollment.

    Pre-dose and post-dose concentrations of cafilzomib

  14. Part 1: Concentrations of elranatamab

    Time frame: Assessed for approximately 2 years.

    Pre-dose and post-dose concentrations of elranatamab

  15. Part 1: Percentage of participants with positive anti-drug antibodies (ADA) against elranatamab

    Time frame: Assessed for approximately 2 years.

    Percent of participants with positive ADA to elranatamab when given in combination with carfilzomib and dexamethasone

  16. Part 2A: Number of Participants with Treatment Emergent Adverse Events (TEAE) by Seriousness and Relationship to Treatment

    Time frame: Assessed from baseline up to 90 days after last dose of study treatment.

    Counts of participants who had TEAEs, defined as newly occurring or worsening after first dose. Relatedness to study drug was assessed by the investigator. Participants with multiple occurrences of an AE within a category were counted once within the category.

  17. Part 2A: Number of Participants with Adverse Events (AE) characterized by type, frequency, severity.

    Time frame: Assessed from baseline up to 90 days after last dose of study treatment.

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

  18. Part 2A: Number of Participants with Clinically Significant Change From Baseline in Laboratory Abnormalities

    Time frame: Accessed from baseline up to 90 days after the last dose of study treatment.

    Laboratory abnormalities as characterized by type, frequency, severity.

  19. Part 2A: Percent of participants with Best Overall Response (BOR)

    Time frame: Assessed for approximately 2 years

    BOR is defined as the best response recorded from treatment start until disease progression/recurrence based on International Myeloma Working Group (IMWG) response criteria.

  20. Part 2A: Percentage of Participants with an Objective Response Rate (ORR)

    Time frame: Assessed from enrollment for approximately 2 years.

    ORR rate is defined as the percent of participants having a Best Overall Response (BOR) of confirmed Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), or Partial Response (PR) according to IMWG.

  21. Part 2A: Percentage of participants with a complete response rate (CRR)

    Time frame: Assessed for approximately 2 years

    Complete Response/ stringent Complete Response (CR+sCR) rate per IMWG response criteria as determined by investigator.

  22. Part 2A: Time to Response (TTR)

    Time frame: Assessed for approximately 2 years.

    TTR is defined, for participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that is subsequently confirmed.

  23. Part 2A: Duration of Response (DOR)

    Time frame: Assessed for approximately 2 years.

    DOR is defined, for participants with an objective response per IMWG criteria, as the time from the first documentation of objective response that is subsequently confirmed, until the first documentation of confirmed progressive disease (PD) per IMWG criteria.

  24. Part 2A: Duration of Complete Response (DOCR)

    Time frame: Assessed for approximately 2 years.

    DOCR is defined, for participants with a Complete Response/stringent Complete Response (CR+sCR) per IMWG criteria, as the time from the first documentation of CR/sCR that is subsequently confirmed, until the first documentation of confirmed progressive disease (PD) per IMWG criteria.

  25. Part 2A: Time of Progression Free Survival (PFS)

    Time frame: Assessed from enrollment until Progressive Disease or death for approximately 2 years.

    Progression free survival (IMWG response criteria)

  26. Part 2A: Time of Overall Survival (OS)

    Time frame: Assessed for approximately 2 years

    OS is the duration of time from first dose of study treatment to death.

  27. Part 2A: Minimal Residual Disease (MRD) Negativity Rate

    Time frame: Assessed for approximately 2 years

    MRD negativity rate is the proportion of participants achieving CR+sCR with negative MRD, per IMWG sequencing criteria, from the date of first dose until the first documentation of confirmed progressive disease (PD), death or start of new anticancer therapy.

  28. Part 2A: Concentrations of maplirpacept

    Time frame: Assessed for approximately 2 years.

    Pre-dose and post-dose concentrations of maplirpacept

  29. Part 2A: Concentrations of elranatamab

    Time frame: Assessed for approximately 2 years.

    Pre-dose and post-dose concentrations of elranatamab

  30. Part 2A: Percentage of participants with positive anti-drug antibodies (ADA) against elranatamab

    Time frame: Assessed for approximately 2 years.

    Percent of participants with positive ADA to elranatamab when given in combination with maplirpacept

  31. Part 2A: Percentage of participants with positive anti-drug antibodies (ADA) against maplirpacept

    Time frame: Assessed for approximately 2 years.

    Percent of participants with positive ADA to elranatamab when given in combination with elranatamab

  32. Part 2B: Number of Participants with Treatment Emergent Adverse Events (TEAE) by Seriousness and Relationship to Treatment

    Time frame: Assessed from baseline up to 90 days after last dose of study treatment.

    Counts of participants who had TEAEs, defined as newly occurring or worsening after first dose. Relatedness to study drug was assessed by the investigator. Participants with multiple occurrences of an AE within a category were counted once within the category.

  33. Part 2B: Number of Participants with Adverse Events (AE) characterized by type, frequency, severity.

    Time frame: Assessed from baseline up to 90 days after last dose of study treatment.

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

  34. Part 2B: Number of Participants with Clinically Significant Change From Baseline in Laboratory Abnormalities

    Time frame: Accessed from baseline up to 90 days after the last dose of study treatment.

    Laboratory abnormalities as characterized by type, frequency, severity.

  35. Part 2B: Percent of participants with Best Overall Response (BOR)

    Time frame: Assessed for approximately 2 years

    BOR is defined as the best response recorded from treatment start until disease progression/recurrence based on International Myeloma Working Group (IMWG) response criteria.

  36. Part 2B: Percentage of Participants with an Objective Response Rate (ORR)

    Time frame: Assessed from enrollment for approximately 2 years.

    ORR rate is defined as the percent of participants having a Best Overall Response (BOR) of confirmed Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), or Partial Response (PR) according to IMWG.

  37. Part 2B: Percentage of participants with a complete response rate (CRR)

    Time frame: Assessed for approximately 2 years

    Complete Response/ stringent Complete Response (CR+sCR) rate per IMWG response criteria as determined by investigator.

  38. Part 2B: Time to Response (TTR)

    Time frame: Assessed for approximately 2 years.

    TTR is defined, for participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that is subsequently confirmed.

  39. Part 2B: Duration of Response (DOR)

    Time frame: Assessed for approximately 2 years.

    DOR is defined, for participants with an objective response per IMWG criteria, as the time from the first documentation of objective response that is subsequently confirmed, until the first documentation of confirmed progressive disease (PD) per IMWG criteria.

  40. Part 2B: Duration of Complete Response (DOCR)

    Time frame: Assessed for approximately 2 years.

    DOCR is defined, for participants with a Complete Response/stringent Complete Response (CR+sCR) per IMWG criteria, as the time from the first documentation of CR/sCR that is subsequently confirmed, until the first documentation of confirmed progressive disease (PD) per IMWG criteria.

  41. Part 2B: Time of Progression Free Survival (PFS)

    Time frame: Assessed from enrollment until Progressive Disease or death for approximately 2 years.

    Progression free survival (IMWG response criteria)

  42. Part 2B: Time of Overall Survival (OS)

    Time frame: Assessed for approximately 2 years

    OS is the duration of time from first dose of study treatment to death.

  43. Part 2B: Minimal Residual Disease (MRD) Negativity Rate

    Time frame: Assessed for approximately 2 years

    MRD negativity rate is the proportion of participants achieving CR+sCR with negative MRD, per IMWG sequencing criteria, from the date of first dose until the first documentation of confirmed progressive disease (PD), death or start of new anticancer therapy.

  44. Part 2B: Concentrations of maplirpacept

    Time frame: Assessed for approximately 2 years.

    Pre-dose and post-dose concentrations of maplirpacept

  45. Part 2B: Concentrations of elranatamab

    Time frame: Assessed for approximately 2 years.

    Pre-dose and post-dose concentrations of elranatamab

  46. Part 2B: Percentage of participants with positive anti-drug antibodies (ADA) against elranatamab

    Time frame: Assessed for approximately 2 years.

    Percent of participants with positive ADA to elranatamab when given in combination with maplirpacept

  47. Part 2B: Percentage of participants with positive anti-drug antibodies (ADA) against maplirpacept

    Time frame: Assessed for approximately 2 years.

    Percent of participants with positive ADA to elranatamab when given in combination with elranatamab

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA

Acronym: MagnetisMM-20

Important dates

Study start
2022
Primary completion
2025
Study completion
2028
First posted
Jan 9, 2023
Registry last updated
Apr 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.